Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

NCT02789332 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

107

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Triple Negative Breast Neoplasms
HRpos Breast Neoplasms
BRCA 1 /2 and / or HRD

Interventions

DRUG: PwO
DRUG: PwCb
DRUG: EC
PROCEDURE: Surgery after neoadjuvant Therapy
OTHER: Stratification

Sponsor

GBG Forschungs GmbH

Collaborators

[object Object]